Radiopharmaceutical developer Immunomedics has appointed Robert DeLuccia as CEO to take over duties previously handled by the company's founder, Dr. David Goldenberg. DeLuccia formerly served as marketing vice president at both Pfizer Laboratories and
Radiopharmaceutical developer Immunomedics has appointed Robert DeLuccia as CEO to take over duties previously handled by the company's founder, Dr. David Goldenberg. DeLuccia formerly served as marketing vice president at both Pfizer Laboratories and Winthrop Pharmaceuticals, as well as U.S. president of Sanofi Winthrop Pharmaceuticals.
DeLuccia will assume immediate management of the company, allowing Goldenberg to center his efforts on Immunomedics' cancer therapeutics research and other projects. DeLuccia's responsibilities will include developing strategies to best use the company's technology and personnel, according to the Morris Plains, NJ-based firm.
Immunomedics manufactures and distributes antibody-based cancer and infection imaging agents throughout the U.S. and Europe. Its products include CEA-Scan, for the detection of colorectal cancer, and LeukoScan, for the diagnosis of bone infection. LeukoScan is currently under review by the Food and Drug Administration.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.